title: From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
abstract: Dengue vaccine development has reached a major milestone with the initiation, in 2010, of the first phase III clinical trial to investigate the Sanofi Pasteur CYD tetravalent dengue vaccine (TDV). The CYD TDV candidate is composed of four recombinant, live, attenuated vaccines (CYD-1-4) based on a yellow fever vaccine 17D (YFV 17D) backbone, each expressing the pre-membrane and envelope genes of one of the four dengue virus serotypes. The vaccine is genetically and phenotypically stable, non-hepatotropic, less neurovirulent than YFV 17D, and does not infect mosquitoes by the oral route. In vitro and in vivo preclinical studies showed that CYD TDV induces controlled stimulation of human dendritic cells, and significant immune responses in monkeys. Scale up and industrialization are being conducted in parallel with preclinical and clinical development to fulfill the needs of phase II/III trials, and to anticipate and facilitate supply and access to vaccine in the countries where the dengue disease burden makes it an urgent public health priority. The vaccine has now been administered to more than 6000 children and adults from dengue endemic and non-endemic areas and no safety concerns have arisen in any of the completed or ongoing trials. A three-dose vaccination regimen induces an immune response against all four serotypes in the large majority of vaccinees. Preexisting flavivirus immunity favors quicker and higher immune responses to CYD TDV, without adversely effecting clinical safety or increasing vaccine viremia. The observed level and nature of the cellular immune responses in humans are consistent with the good safety and immunogenicity profile of the vaccine. Preliminary results of an ongoing, proof-of-concept efficacy and large scale safety study in Thai children are expected by the end of 2012. Here we discuss the different steps and challenges of developing CYD TDV, from research to industrialization, and summarize some of the challenges to the successful introduction of a dengue vaccine into immunization programs.
authors: Research and Development, Sanofi Pasteur, 69280 Marcy l'Etoile, France. bruno.guy@sanofipasteur.com
authors: Bruno
authors: B
authors: Guy
authors: Beatrice
authors: B
authors: Barrere
authors: Claire
authors: C
authors: Malinowski
authors: Melanie
authors: M
authors: Saville
authors: Remy
authors: R
authors: Teyssou
authors: Jean
authors: J
authors: Lang
mesh_terms: D032761:Animal Experimentation; D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D003715:Dengue / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology*; D003716:Dengue Virus / Q000235:genetics* / Q000276:immunology*; D055808:Drug Discovery; D005602:France; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects / Q000379:methods; D014611:Vaccination / Q000009:adverse effects / Q000379:methods; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D022341:Yellow Fever Vaccine / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
chemical_list: C000603176:CYD-TDV vaccine; D053059:Dengue Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D022341:Yellow Fever Vaccine